CD25, CD28 and CD38 expression in peripheral blood lymphocytes as a tool to predict acute rejection after liver transplantation

Clinical Transplantation

Volumn 22, Issue 4, 2008, Pages 494-501

  Boleslawski, Emmanuel ^a   Benothman, Samia ^a   Grabar, Sophie ^b   Correia, Leonor ^a   Podevin, Philippe ^a   Chouzenoux, Sandrine ^a   Soubrane, Olivier ^b   Calmus, Yvon ^a,b   Conti, Filomena ^a,b  

^a UPRES EA 1833   (France)

^b Hôpital Cochin ^*  (France)

Author keywords

Acute rejection; Bacterial infections; CMV infection

Indexed keywords

ANTIBIOTIC AGENT; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ALPHA; METHYLPREDNISOLONE; OKT 3; PREDNISOLONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BACTERIAL INFECTION; CLINICAL ARTICLE; CLINICAL INDICATOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; FLOW CYTOMETRY; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PERIPHERAL LYMPHOCYTE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; UNIVARIATE ANALYSIS;

ADULT; ANTIGENS, CD28; ANTIGENS, CD38; CYCLOSPORINE; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; T-LYMPHOCYTES; TACROLIMUS; YOUNG ADULT;

EID: 48249125001     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00815.x     Document Type: Article

References (30)

1. Lindholm A. Cyclosporine A: Clinical experience and therapeutic drug monitoring. Ther Drug Monit 1995: 17: 631.
2. Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: A practical measure of cyclosporine effect. Clin Chem 1999: 45: 1477.
3. Le Moine A, Goldman M, Abramowicz D. Multiple pathways to allograft rejection. Transplantation 2002: 73: 1373.
4. Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996: 381: 434.
5. Dong VM, Yuan X, Coito AJ et al. Mechanisms of targeting CD28 by signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation 2002: 73: 1310.
6. Baan CC, Weimar W. Intragraft cytokine gene expression: Implications for clinical transplantation. Transpl Int 1999: 11: 169.
7. Hirose R. Pros and cons of using Interleukin-2 receptor antibodies in liver transplant recipients. Liver Transpl 2002: 8: 143.
8. Calmus Y, Scheele JR, Gonzalez-Pinto I et al. Immunoprophylaxis with basiliximab, a chimeric anti-Interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002: 8: 123.
9. Malavasi F, Funaro A, Roggero S et al. Human CD 38: A glycoprotein in search of a function. Immunol Today 1994: 15: 95.
10. + T-cell subset in kidney transplant recipients. Transplantation 1998: 65: 279.
11. Anonymous. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997: 25: 658.
12. The French Metavir Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994: 20: 15.
13. Klintmalm GB, Nery JR, Husberg BS, Gonwa TA, Tillery GW. Rejection in liver transplantation. Hepatology 1989: 10: 978.
14. Brunt EM, Peters MG, Flye MW, Hanto DW. Day-5 protocol liver allograft biopsies document early rejection episodes and are predictive of recurrent rejection. Surgery 1992: 111: 511.
15. Mor E, Gonwa TA, Husberg BS, Goldstein RM, Klintmalm GB. Late-onset acute rejection in orthotopic liver transplantation-associated risk factors and outcome. Transplantation 1992: 54: 821.
16. Cakaloglu Y, Tredger J, Devlin J, Williams R. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK-506 and cyclosporine in liver transplant recipients. Hepatology 1994: 20: 309.
17. Lemaire M, Tillement JP. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 1982: 34: 715.
18. Boleslawski E, Conti F, Sanquer S et al. Evaluation of Interleukin-2 expression and calcineurin activity in peripheral blood mononuclear cells for monitoring immunosuppressive therapy after liver transplantation. Transplantation 2004: 77: 1815.
19. Batiuk T, Pazderka F, Halloran P. Calcineurin activity is only partially inhibited in leucocytes of cyclosporine-treated patients. Transplantation 1995: 59: 1400.
20. Caruso R, Perico N, Cattananeo D et al. Whole-blood calcineurin activity is not predicted by cyclosporin blood concentration in renal transplant recipients. Clin Chem 2001: 47: 1679.
21. Grinyo JM, Cruzado JM, Millan O et al. Low-dose cyclosporine with mycophenolate mofetil induces similar calcineurin activity and cytokine inhibition as dose standard-dose cyclosporine in stable renal allografts. Transplantation 2004: 78: 1400.
22. Pacheco-Silva A. Immune function, as assessed by the ImmuKnow assay, correlates with clinical outcomes in transplant recipients. Nat Clin Pract Nephrol 2007: 3: 196.
23. Kowalski RJ, Post DR, Mannon RB et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 2006: 82: 663.
24. van den Berg AP, Twilhaar WN, Mesander G et al. Quantification of immunosuppression by flow cytometric measurement of the capacity of T cells for interleukin-2 production. Transplantation 1998: 65: 1066.
25. + T lymphocyte compartment. Transplantation 1997: 63: 693.
26. + T cells recognizing CMVpp65 are present but display functional impairment. Clin Exp Immunol 2003: 132: 96.
27. Guo L, Li XK, Enosawa S et al. Significant enhancement by anti-ICOS antibody of suboptimal tacrolimus immunosuppression in rat liver. Liver Transpl 2004: 10: 743.
28. Bofill M, Borthwick NJ. CD38 in health and disease. Chem Immunol 2000: 75: 218.
29. + T cells in HIV-1-infected patients. AIDS 1996: 10: 827.
30. G raca L, T hompson S, L in CY, A dams E, C obbold SP, W aldmann H. Both CD4(+)CD25(+) and CD4(+)CD25(-) regulatory cells mediate dominant transplantation tolerance. J Immunol 2002: 168: 5558.